[1]
|
Mansfield, S.A., Williams, R.F. and Iacobas, I. (2020) Vascular Tumors. Seminars in Pediatric Surgery, 29, Article ID: 150975. https://doi.org/10.1016/j.sempedsurg.2020.150975
|
[2]
|
邹运, 陈辉, 林晓曦. ISSVA血管瘤和脉管畸形新分类(2018版) [J]. 中国美容整形外科杂志, 2018, 29(12): 711-713+771-780.
|
[3]
|
Briones, M. and Adams, D. (2021) Neonatal Vascular Tumors. Clinics in Perinatology, 48, 181-198.
https://doi.org/10.1016/j.clp.2020.11.011
|
[4]
|
Rodríguez Bandera, A.I., Sebaratnam, D.F., Wargon, O. and Wong, L.-C.F. (2021) MBBS Hons Mab, Owhm C, et al. Infantile Hemangioma. Part 1: Epidemiology, Pathogenesis, Clinical Presentation and Assessment. Journal of the American Academy of Dermatology, 85, 1379-1392. https://doi.org/10.1016/j.jaad.2021.08.019
|
[5]
|
Léauté-Labrèze, C., Harper, J.I. and Hoeger, P.H. (2017) Infantile Haemangioma. Lancet, 390, 85-94.
https://doi.org/10.1016/S0140-6736(16)00645-0
|
[6]
|
Sebaratnam, D.F., Rodríguez Bandera, A.I., Wong, L.-C.F. and Wargon, O. (2021) Infantile Hemangioma. Part 2: Management. Journal of the American Academy of Dermatology, 85, 1395-1404.
https://doi.org/10.1016/j.jaad.2021.08.020
|
[7]
|
Cîrstoveanu, C., Bizubac, A.M., Mustea, C., et al. (2021) Antipro-liferative Therapy with Sirolimus and Propranolol for Congenital Vascular Anomalies in Newborns (Case Reports). Ex-perimental and Therapeutic Medicine, 22, Article No. 1097. https://doi.org/10.3892/etm.2021.10531
|
[8]
|
Xu, M.-N., Zhang, M., Xu, Y., Wang, M. and Yuan, S.-M. (2018) Individualized Treatment for Infantile Hemangioma. Journal of Craniofacial Surgery, 29, 1876-1879. https://doi.org/10.1097/SCS.0000000000004745
|
[9]
|
Filoni, A., Ambrogio, F., De Marco, A., Pacific, A. and Bonamonte, D. (2021) Topical Beta-Blockers in Dermatologic Therapy. Dermatologic Therapy, 34, e15016. https://doi.org/10.1111/dth.15016
|
[10]
|
Lin, Z., Zhang, B., Yu, Z. and Li, H. (2020) The Effectiveness and Safety of Topical Β-Receptor Blocker in Treating Superficial Infantile Haemangiomas: A Meta-Analysis Including 20 Studies. British Journal of Clinical Pharmacology, 86, 199-209. https://doi.org/10.1111/bcp.14196
|
[11]
|
Muñoz-Garza, F.Z., Ríos, M., Roé-Crespo, E., et al. (2021) Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. JAMA Dermatology, 157, 583-587. https://doi.org/10.1001/jamadermatol.2021.0596
|
[12]
|
Zheng, L. and Li, Y. (2018) Effect of Topical Timolol on Response Rate and Adverse Events in Infantile Hemangioma: A Me-ta-Analysis. Archives of Dermatological Research, 310, 261-269. https://doi.org/10.1007/s00403-018-1815-y
|
[13]
|
Danarti, R., Ariwibowo, L., Radiono, S. and Budiyanto, A. (2016) Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticoster-oids—A Single-Center Experience of 278 Cases. Dermatology, 232, 566-571. https://doi.org/10.1159/000448396
|
[14]
|
Zhang, J.-Y., Lan, S.-J., Liu, M., et al. (2021) Topical Timolol Combined Intralesional Injection of Diprospan in the Treatment of Elevated Localized Mixed Infantile Hemangiomas and a Discus-sion for Proper Timing for Injection. Journal of Craniofacial Surgery, 32, 988-990. https://doi.org/10.1097/SCS.0000000000007523
|
[15]
|
Chinnadurai, S., Fonnesbeck, C., Snyder, K.M., et al. (2016) Pharmacologic Interventions for Infantile Hemangioma: A Meta-Analysis. Pediatrics, 137, e20153896. https://doi.org/10.1542/peds.2015-3896
|
[16]
|
Novoa, M., Baselga, E., Beltran, S., et al. (2018) Interventions for In-fantile Haemangiomas of the Skin. Cochrane Database of Systematic Reviews, 4, Article ID: CD006545. https://doi.org/10.1002/14651858.CD006545.pub3
|
[17]
|
Zhang, L., Zheng, J.W. and Yuan, W. (2015) Treatment of Alarming Head and Neck Infantile Hemangiomas with Interferon-α2a: A Clinical Study in Eleven Consecutive Patients. Drug Design, Development and Therapy, 9, 723-727.
https://doi.org/10.2147/DDDT.S67682
|
[18]
|
Chai, Y., Zhou, Z., Song, J., et al. (2019) Safety of Intralesional Injec-tion of Lauromacrogol Combined with Triamcinolone for Infantile Hemangiomas. The Journal of Dermatology, 46, 770-776.
https://doi.org/10.1111/1346-8138.14992
|
[19]
|
Sabry, H.H., Sorour, N.E. and Akl, E.M. (2020) Intralesional Injec-tion of Bevacizumab versus Triamcinolone Acetonide in Infantile Hemangioma. Journal of Dermatological Treatment, 31, 279-284.
https://doi.org/10.1080/09546634.2019.1590521
|
[20]
|
Hutchinson, A.K., Kraker, R.T., Pineles, S.L., et al. (2019) The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants. Ophthalmology, 126, 146-155. https://doi.org/10.1016/j.ophtha.2018.07.023
|
[21]
|
Püttgen, K., Lucky, A., et al. (2016) Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 138, e20160355. https://doi.org/10.1542/peds.2016-0355
|
[22]
|
Pandey, V., Tiwari, P., Imran, M., et al. (2021) Adverse Drug Reac-tions Following Propranolol in Infantile Hemangioma. Indian Pediatrics, 58, 753-755. https://doi.org/10.1007/s13312-021-2286-3
|
[23]
|
Li, G., Xu, D.-P., Tong, S., et al. (2016) Oral Propranolol with Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. Journal of Cra-niofacial Surgery, 27, 56-60.
https://doi.org/10.1097/SCS.0000000000002221
|
[24]
|
Knöpfel, N., Oesch, V., Theiler, M., Szello, P. and Weibel, L. (2020) Rebound of Involuted Infantile Hemangioma after Administration of Salbutamol. Pediatrics, 145, e20191942. https://doi.org/10.1542/peds.2019-1942
|
[25]
|
Fernando, S.J., Leitenberger, S., Majerus, M., Krol, A. and MacAr-thur, C.J. (2016) Use of Intravenous Propranolol for Control of a Large Cervicofacial Hemangioma in a Critically Ill Ne-onate. International Journal of Pediatric Otorhinolaryngology, 84, 52-54. https://doi.org/10.1016/j.ijporl.2016.02.005
|
[26]
|
Bennett, M.L., Fleischer Jr., A.B., Chamlin, S.L. and Frieden, I.J. (2001) Oral Corticosteroid Use Is Effective for Cutaneous Hemangiomas: An Evidence-Based Evaluation. Archives of Dermatology, 137, 1208-1213.
https://doi.org/10.1001/archderm.137.9.1208
|
[27]
|
Satterfield, K.R. and Chambers, C.B. (2019) Current Treatment and Management of Infantile Hemangiomas. Survey of Ophthalmology, 64, 608-618. https://doi.org/10.1016/j.survophthal.2019.02.005
|
[28]
|
Al-Haddad, C., El Salloukh, N.A. and El Moussawi, Z. (2019) β-Blockers in the Treatment of Periocular Infantile Hemangioma. Current Opinion in Ophthalmology, 30, 319-325. https://doi.org/10.1097/ICU.0000000000000591
|
[29]
|
Polites, S.F., Watanabe, M., Crafton, T., et al. (2019) Surgical Resection of Infantile Hemangiomas Following Medical Treatment with Propranolol versus Corticoster-oids. Journal of Pediatric Surgery, 54, 740-743.
https://doi.org/10.1016/j.jpedsurg.2018.08.001
|
[30]
|
Polites, S.F., Rodrigue, B.B., Chute, C., Hammill, A. and Dasgupta, R. (2018) Propranolol versus Steroids for the Treatment of Ulcerated Infantile Hemangiomas. Pediatric Blood & Cancer, 65, e27280.
https://doi.org/10.1002/pbc.27280
|
[31]
|
Zaher, H., Rasheed, H., El-Komy, M.M., et al. (2016) Propranolol versus Captopril in the Treatment of Infantile Hemangioma (IH): A Randomized Controlled Trial. The Journal of the American Academy of Dermatology, 74, 499-505.
https://doi.org/10.1016/j.jaad.2015.09.061
|
[32]
|
Cho, Y.J., Kwon, H., Kwon, Y.J., et al. (2021) Effects of Sirolimus in the Treatment of Unresectable Infantile Hemangioma and Vascular Malformations in Children: A Single-Center Expe-rience. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 9, 1488-1494. https://doi.org/10.1016/j.jvsv.2021.03.014
|
[33]
|
Jin, W.-W., Tong, Y., Wu, J.-M., Quan, H.-H. and Gao, Y. (2020) Observation on the Effects of 595-nm Pulsed Dye laser and 755-nm Long-Pulsed Alexandrite Laser on Sequential Ther-apy of Infantile Hemangioma. Journal of Cosmetic and Laser Therapy, 22, 159-164. https://doi.org/10.1080/14764172.2020.1783452
|
[34]
|
Filaj, V., Jorgaqi, E. and Byzhyti, M. (2021) Our Experience in the Treatment of Hemangioma with Intense Pulsed Light Laser: A 10 Year Study in Albania. Dermatologic Therapy, 34, e14880. https://doi.org/10.1111/dth.14880
|
[35]
|
Ying, H., Zou, Y., Yu, W., et al. (2017) Prospective, Open-Label, Rater-Blinded and Self-Controlled Pilot Study of the Treatment of Proliferating Superficial Infantile Heman-giomas with 0.5% Topical Timolol Cream versus 595-nm Pulsed Dye Laser. The Journal of Dermatology, 44, 660-665. https://doi.org/10.1111/1346-8138.13747
|
[36]
|
Chelleri, C., Monzani, N.A., Gelmetti, C., et al. (2020) Residual Le-sions after Pharmacological and Dye-Laser Treatment of Infantile Hemangiomas: Critical Review of 432 Cases. Lasers in Surgery and Medicine, 52, 597-603.
https://doi.org/10.1002/lsm.23205
|
[37]
|
Bleve, C., Conighi, M.L., Valerio, E., et al. (2022) Surgical Management of Large Scalp Infantile Hemangioma in 30-Month-Old Infant. La Pediatria Medica E Chirurgica, 44, Article No. 279. https://doi.org/10.4081/pmc.2022.279
|
[38]
|
Men, C.J., Ediriwickrema, L.S., Paik, J.S., et al. (2020) Surgical Inter-vention of Periocular Infantile Hemangiomas in the Era of β-Blockers. Ophthalmic Plastic and Reconstructive Surgery, 36, 70-73.
https://doi.org/10.1097/IOP.0000000000001466
|
[39]
|
Cheng, J., Liu, B. and Lee, H.-J. (2019) Outcomes of Surgi-cal Treatment for Hemangiomas. Pediatric Dermatology, 36, 207-212. https://doi.org/10.1111/pde.13751
|
[40]
|
庞筱安, 韦智晓, 李俊红, 等. 90Sr敷贴在皮肤血管瘤治疗中的应用[J]. 中华核医学与分子影像杂志, 2021, 41(7): 435-437.
|